Blood Transfusion Risks: Disease Transmission, Regional Differences, and Safety Data

How Safe Is a Blood Transfusion?

The U.S. blood supply is safer than at any point in history, and the risk of receiving an infected unit is genuinely small. But small is not zero — and some patients, particularly those who require multiple transfusions or live in higher-risk regions, face elevated cumulative exposure.

Understanding what the actual numbers mean helps you ask the right questions before consenting to a transfusion. Every unit of donated blood in the U.S. undergoes 11–12 mandatory tests, but testing has limits: every test has a detection window, and some pathogens have no approved routine test at all.

What Diseases Can Be Transmitted Through Blood Transfusion?

Hepatitis B

Hepatitis B is transmitted through parenteral and sexual routes, with an incubation period of 30–180 days. Surface antigen (HBsAg) testing and core antibody testing are required on all donated units. The estimated transmission risk in the U.S. is approximately 1 in 66,000 per unit.

People with chronic hepatitis B infection who received transfusions before modern surface antigen screening became mandatory are at elevated long-term risk of liver disease and liver cancer.

Hepatitis C

Hepatitis C is the most significant transfusion-transmitted disease in U.S. history. Before antibody screening was introduced in 1990, roughly 300,000 people acquired hepatitis C through blood transfusions. The virus now affects over 4 million Americans in chronic form and is the primary reason for liver transplantation in the country.

The estimated transmission risk today is approximately 1 in 121,000 per unit. People who received transfusions before 1991 remain at elevated risk and should be tested if they haven’t been already.

HIV

HIV testing of donated blood began in 1985 with antibody detection, expanded in 1996 to include p24 antigen testing (which detects the virus earlier in infection). The estimated transmission risk stands at approximately 1 in 563,000 per unit transfused — one of the lowest rates globally.

The residual risk that remains is primarily from donations made during the “window period” — the time between initial infection and detectable antibodies. Nucleic acid amplification testing (NAT), introduced in the late 1990s, further shortened this window.

HTLV-1 and HTLV-2

Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus endemic to Japan, the Caribbean, and parts of Africa. It is linked to adult T-cell leukemia and tropical spastic paraparesis, a progressive neurological disorder. HTLV-2 has been associated with similar neurological conditions. Routine antibody testing for both is required on donated blood. The combined transmission risk is approximately 1 in 641,000 per unit.

Cytomegalovirus (CMV)

CMV is carried by over half the adult population in a dormant state within white blood cells. For most recipients, transfusion-transmitted CMV causes no symptoms. In immunocompromised patients — transplant recipients, premature infants, HIV-positive individuals — CMV can cause severe and life-threatening disease. CMV-negative or leukoreduced blood products are used for these high-risk patients.

Creutzfeldt-Jakob Disease (CJD)

Variant CJD (vCJD), linked to bovine spongiform encephalopathy (mad cow disease), is theoretically transmissible via blood. No approved screening test exists. Several transfusion-associated vCJD cases have been documented in the United Kingdom. Donors who spent extended time in the UK during the at-risk period are permanently deferred in the U.S.

Bacterial Contamination

Bacteria can enter blood during the collection process and multiply during storage. Platelets, stored at room temperature for up to 5 days, carry the highest risk. Bacterial contamination causes an estimated 30 deaths annually in the U.S. and represents a significant proportion of transfusion fatalities. No routine, cost-effective screening test was available as of the data period covered here, though enhanced point-of-care culture testing has since been implemented at many centers.

Other Pathogens

The following diseases can also be transmitted through transfusion, though risks are lower or less well-quantified:

• Malaria — Donors with recent travel to endemic areas are deferred; no routine screening test
• Chagas disease (Trypanosoma cruzi) — Growing concern with increased immigration from endemic Central and South America; FDA-licensed screening tests now available
• Babesiosis — Tick-borne parasitic infection; concentrated in the Northeast U.S.; no universally implemented screening as of earlier data periods
• Hepatitis G — Related to hepatitis C but less well understood; clinical significance unclear
• Toxoplasmosis — Relevant mainly for immunocompromised recipients
• Lyme disease — Theoretical risk; no documented transfusion transmission

Does Your Location Affect Transfusion Risk?

Yes — geography matters. Based on 1994–1995 data from the United States, disease transmission risk varied significantly by region:

The Southeast carried nearly 7 times the risk of the Central region. Several factors contribute to regional variation: prevalence of infectious diseases in the local donor population, demographics, socioeconomic factors affecting donor pool characteristics, and local blood center practices.

An important caveat: these figures are from 1994–1995. Overall national risk has almost certainly improved since then due to enhanced screening technologies, particularly NAT testing. However, relative regional differences may persist because they reflect underlying disease prevalence in donor populations, not just testing practices. The practice of transporting blood products across state lines and pooling plasma from tens of thousands of donors may increasingly equalize regional risk over time.

What Are Non-Infectious Risks of Transfusion?

Disease transmission is only one category of transfusion risk. Non-infectious risks include:

• Immune reactions — From mild febrile reactions to fatal acute hemolytic reactions; see Transfusion Reactions: Symptoms and Treatment
• Alloantibody formation — Developing antibodies against donor antigens, complicating future transfusions
• Transfusion-related acute lung injury (TRALI) — Leading cause of transfusion fatalities in the U.S.
• Circulatory overload (TACO) — Fluid overload, particularly in elderly and cardiac patients
• Iron overload — Cumulative iron toxicity in patients receiving many units over time
• Graft-versus-host disease — Rare but often fatal in immunocompromised recipients
• Clerical errors — Wrong-patient transfusions; estimated at 1 in 30,000 to 1 in 50,000

How Does the Blood Safety System Work?

The FDA mandates a five-layer safety system for all donated blood:

1. Donor screening — Health and lifestyle questionnaires to identify and defer at-risk donors
2. Blood testing — 11–12 mandatory laboratory tests on every donated unit
3. Donor deferral registries — Databases of previously deferred donors (not nationally coordinated as of earlier periods)
4. Quarantine — Units held until required testing is complete
5. Error reporting — Required investigation and reporting of safety breaches and fatalities

A significant vulnerability in this system: donor questionnaires rely on self-disclosure. The U.S. uses an honor system — donors must truthfully answer questions about behaviors and exposures that would disqualify them. Documentation from FDA enforcement records shows that in some cases, blood was collected from donors who had raised concerns about their own eligibility.

How Can You Reduce Your Personal Risk?

For patients facing elective surgery where transfusion is anticipated:

• Ask about autologous donation — Using your own pre-stored blood eliminates both infectious and immune-based risks
• Discuss the necessity — Request that transfusion triggers (the hemoglobin level at which transfusion is initiated) be conservative; current guidelines suggest transfusion is rarely needed above hemoglobin levels of 100 g/L
• Know your rights — Informed consent for transfusion requires full disclosure of risks and alternatives; see Informed Consent for Blood Transfusion
• Disclose your history — Previous reactions, recent international travel, or known antibodies should be communicated before any procedure